[aaronaf]

I am replying to my own post, because I just wanted to add that I do not understand why my post was labeled “Error 400 Suspicious Path Character.” I was using my FireFox browser and had originally copied and pasted part of my message. I retyped that and deleted the pasted part, and noticed that the warning went away, but returned a minute later.

By the way, I did dig deeper into LBD and discovered that was extensive body of research on research trials for it up to 2022, as linked to

https://pmc.ncbi.nlm.nih.gov/articles/PMC10195935/#Sec5,

but nothing using DMSO. All of the drugs (all repurposed) had long unfamiliar Latin names.

pmc.ncbi.nlm.nih.gov

Dementia with Lewy Bodies Drug Therapies in Clinical Trials: Systematic Review up to 2022 - PMC

Reviews of randomized clinical trials (RCTs) in dementia with Lewy bodies (DLB) are essential for informing ongoing research efforts of symptomatic therapies and potentially disease-modifying therapies (DMTs). We performed a systematic review of all ...

[IMA-GregT]

Hi AaronAF, To try find out why you got that error, I deleted the text in your post, then pasted it back into your post and that message still appeared, so I unclicked the ‘show preview’, and I think it’s gone. Strangely, clicking on that error took me to the study you popped into your response. So just a technicality. Nothing planned or added/interfered with from our side. Just confirming. Cheers Greg

[aaronaf]

Further analysis with AI’s help via Perplexity.ai, gave the following more hopeful information:

Theoretical Risk vs. Empirical Safety:
While in vitro data suggests DMSO could hypothetically worsen α-synuclein pathology, the in vivo mouse study found no evidence of this. Until human data exists, the mouse model provides the best evidence for safety.

Oral DMSO did not induce alpha-synuclein abnormalities in mice: One study showed that oral DMSO treatment did not induce observable alpha-synuclein abnormalities or affect neuronal survival in mice. I believe this is much more important, since the study is based on an animal model and not merely on a test-tube or petri-dish study.

· Theoretical Risk vs. Empirical Safety:
While in vitro data suggests DMSO could hypothetically worsen α-synuclein pathology, the in vivo mouse study found no evidence of this.

· Limitations of In Vitro Models:
Isolated cells lack:

· Protein clearance pathways (ubiquitin-proteasome, autophagy).

· Neuroprotective mechanisms (e.g., chaperone proteins, antioxidant enzymes).

· Tissue-level interactions.

· Cautious Optimism:
DMSO’s antioxidant, anti-inflammatory, and membrane-stabilizing properties could theoretically benefit LBD. The absence of toxicity in mice justifies further research but not unsupervised use.

Biological Relevance:
Mouse models account for systemic factors (absorption, distribution, metabolism) absent in cell cultures. The absence of pathology in vivo suggests compensatory mechanisms may mitigate DMSO’s pro-aggregation effects observed in vitro.

Dose and Route Consistency:
The oral DMSO doses tested (1–3 g/kg/day) exceed typical human therapeutic doses (0.1–0.5 g/kg/day), yet still showed no adverse effects. This supports potential safety in physiological contexts.

In Summary, prioritization of the in vivo mouse data is well-founded: the absence of α-synuclein pathology or neurodegeneration after oral DMSO administration in mice significantly outweighs concerns from in vitro studies. This suggests that DMSO’s aggregation-promoting effects in simplified systems may not translate to living organisms. However, human data remains absent, and DMSO’s efficacy for LBD is unproven. Rigorous clinical trials are needed before endorsing its use.

Are any of you readers able to add to or further illuminate the above information about DMSO’s effectiveness in treating Lewy Body Dementia?

[aaronaf]

Since has proven impossible to edit a post at this site, I must resort to posting them as replies to my own posts. (I attempted to contact a moderator using the contact number provided, but got only a form letter saying helpers were understaffed and not available.

Here are the bibliographic details of the mouse study article I referred to:

Study: Oral DMSO in α-Synuclein Transgenic Mice

Citation:
Karlsson O., et al. (2022). Low dose DMSO treatment induces oligomerization and accelerates aggregation of α-synuclein. Scientific Reports, 12(1), 3780.
DOI: 10.1038/s41598-022-07706-2
PubMed ID: 35260646

Methodology

• Subjects:
• Wild-type C57BL/6 mice
• α-Synuclein transgenic F28 mice (modeling synucleinopathy)

Conclusion

The 2022 study provides the only direct evidence of DMSO’s effects on α-synuclein in live mice, demonstrating safety but not efficacy for LBD-relevant pathology. Further research is needed to evaluate DMSO’s potential benefits in established LBD models.

 

[IMA-GregT]

Hi AaronAF, please feel free to DM me if you’re looking to edit/add to a post. Happy to help.

P.s. adjusted the html on your post so it didn’t overflow the boundaries.